Clinical Trial Detail

NCT ID NCT04090710
Title SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (CYTOSHRINK)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ontario Clinical Oncology Group (OCOG)
Indications

renal cell carcinoma

Therapies

Nivolumab

Ipilimumab + Nivolumab

Age Groups: senior adult child

No variant requirements are available.